Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.

10 Sep 2021

Scientists assess SARS-CoV-2 mutants in ferret hosts

In a paper recently uploaded to the preprint server bioRxiv* by the cause of SARS-CoV-2 mutations observed in mink and ferrets is investigated, and the danger posed by such mutations to humans assessed.

26 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers in the United States have developed a new model for testing mutations in the four structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Aug 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

New approach to gene therapy uses common pain reliever to fight against genetic diseases

Researchers have developed a new approach to gene therapy that leans on the common pain reliever acetaminophen to force a variety of genetic diseases into remission.

14 Jun 2021

Humoral innate pattern recognition molecules against SARS-CoV-2

In a paper recently uploaded to the preprint server medRxiv by Garlanda et al. (June 8th, 2021), humoral pattern recognition molecules are explored for affinity towards SARS-CoV-2, contributing to unraveling the role of these molecules in COVID-19 disease progression.

13 Jun 2021

AMSBIO's custom lentivectors for labeling organoids

AMSBIO have supplied custom lentivectors to Francesco Pampaloni and his team at the Buchmann Institute for Molecular Life Sciences in Frankfurt, Germany allowing them to visualize cell nuclei and F-actin cytoskeleton in their organoids.

From AMS Biotechnology 1 Jun 2021

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

The study, published in the journal Phytomedicine, characterized an active compound, corilagin (a derivative from Phyllanthus urinaria), as potential SARS-CoV-2 entry inhibitors for its preventive application in daily antiviral hygiene products.

31 May 2021

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

A new study by researchers from Taiwan and the US suggests that the removal of unnecessary glycans from spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposes highly conserved sequences and opens the door for the development of broadly protective vaccines against the virus and its variants.

28 May 2021

Investigational gene therapy can restore immune function in children with inherited immunodeficiency disorder

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

12 May 2021

Experimental gene therapy successfully treats children born without an immune system

An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.

11 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021